DOCSLIB.ORG

GABABR-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GABABR-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells S Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/05/05/mol.116.107854.DC1 1521-0111/92/3/265–277$25.00 https://doi.org/10.1124/mol.116.107854 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:265–277, September 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics MOLECULAR PHARMACOLOGY IN CHINA GABABR-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells s Shuai Xia, Cong He, Yini Zhu, Suyun Wang, Huiping Li, Zhongling Zhang, Xinnong Jiang, and Jianfeng Liu Downloaded from Cell Signaling Laboratory, College of Life Science and Technology, Collaborative Innovation Center for Genetics and Development, and Key Laboratory of Molecular Biophysics of Ministry of Education, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China Received December 14, 2016; accepted April 14, 2017 molpharm.aspetjournals.org ABSTRACT G protein–coupled receptors (GPCRs) and receptor tyrosine ERK1/2 by a mechanism that is dependent on Gi/o protein and kinases (RTKs) act in concert to regulate cell growth, pro- that requires matrix metalloproteinase–mediated proligand liferation, survival, and migration. Metabotropic GABAB receptor shedding. Positive allosteric modulators (PAMs) of GABABR, (GABABR) is the GPCR for the main inhibitory neurotransmitter such as CGP7930, rac-BHFF, and GS39783, can function as GABA in the central nervous system. Increased expression of PAM agonists to induce EGFR transactivation and subsequent GABABR has been detected in human cancer tissues and cancer ERK1/2 activation. Moreover, both baclofen and CGP7930 cell lines, but the role of GABABR in these cells is controversial promoted cell migration and invasion through EGFR signaling. and the underlying mechanism remains poorly understood. In summary, our observations demonstrated that GABABR at ASPET Journals on September 28, 2021 Here, we investigated whether GABABR hijacks RTK signaling transactivated EGFR in a ligand-dependent mechanism to to modulate the fates of human prostate cancer cells. RTK promote prostate cancer cell migration and invasion, thus array analysis revealed that the GABABR-specific agonist providing new insights into developing a novel strategy for baclofen selectively induced the transactivation of EGFR in prostate cancer treatment by targeting neurotransmitter PC-3 cells. EGFR transactivation resulted in the activation of signaling. Introduction effective in some human malignancies (Rask-Andersen et al., 2014), have been used as single agents or in combination with Prostate cancer (PCa) is the second most frequently chemotherapy in clinical trials in patients with castration- diagnosed cancer in men worldwide (Torre et al., 2015). resistant PCa; however, the results were not promising Currently, few therapeutic options are available for patients (Jakobovits, 2008; Gallick et al., 2012; Molife et al., 2014; with advanced PCa. Tyrosine kinase inhibitors, which are Ojemuyiwa et al., 2014; Modena et al., 2016). Therefore, new mechanism-based inhibitors need to be developed to treat PCa The study was financially supported by grants from National Natural patients. Since neurotransmitters have modulatory effects on Science Foundation of China [Grants 31170790, 31225011, 31420103909, and 31371423]; start funding from The Ministry of Education, China, indepen- tumor cells, the potential roles of receptors for neurotrans- dent innovation research funding from Huazhong University of Science and mitters in tumors have attracted more and more research Technology, Wuhan, China [Grant M2009047]; the Fundamental Research Funds for the Central Universities, China [Grant 0118170132/2016YXMS25]; interest (Schuller, 2008a). the Natural Science Foundation of Hubei Province [Grant 2014CFA010]; the GABA is a main inhibitory neurotransmitter in the verte- Program of Introducing Talents of Discipline to Universities from the Ministry of brate central nervous system. Metabotropic GABA receptor Education of China [Grant B08029]; and the Program for Changjiang Scholars B and Innovative Research Team in University [Grant PCSIRT: IRT13016]. (GABABR), a G protein–coupled receptor (GPCR) family S.X. and C.H. contributed equally to this work. member, is an obligatory heterodimer composed of GABAB1 https://doi.org/10.1124/mol.116.107854. s This article has supplemental material available at molpharm. and GABAB2 subunits. The extracellular domain of the aspetjournals.org. GABAB1 subunit has a ligand-binding site for GABA, agonists, ABBREVIATIONS: AR, amphiregulin; CM, conditioned medium; DMSO, dimethylsulfoxide; EGF, epithelial growth factor; EGFR, epithelial growth factor receptor; ELISA, enzyme-linked immunosorbent assay; ERK1/2, extracellular signal–regulated kinase 1/2; FBS, fetal bovine serum; HB-EGF, heparin-binding epithelial growth factor; IGF-1R, insulin-like growth factor receptor 1; GABABR, metabotropic GABAB receptor; GPCR, G protein– coupled receptor; HRP, horseradish peroxidase; MMP, matrix metalloproteinase; p, phosphorylated; PAM, positive allosteric modulator; PBS, phosphate-buffered saline; PCa, prostate cancer; PTX, pertussis toxin; RIPA, radioimmunoprecipitation assay; RT, room temperature; RTK, receptor tyrosine kinase; SFM, serum-freemedium;TCL,totalcelllysate;TGF-a, transforming growth factor-a;TMB,tetramethylbenzidine. 265 266 Xia et al. or antagonists. Whereas the extracellular domain of the pEGFR (Y1045), pEGFR (Y1068), pEGFR (Y1086), pEGFR (Y1148), b GABAB2 subunit lacks the ligand-binding capacities, the pEGFR (Y1173), EGFR, -actin, EGFR antibody-conjugated sepharose beads, and horseradish peroxidase (HRP)–conjugated secondary GABAB2 subunit is responsible for Gi/o protein coupling. It has been shown that specific allosteric modulators bind to antibodies against mouse and rabbit IgG were purchased from Cell Signaling Technology (Danvers, MA). Anti-phosphotyrosine antibody GABA subunit transmembrane domain (Bettler et al., 2004; B2 4G10, 4G10-conjugated agarose beads, and EGFR-neutralizing antibody Pinard et al., 2010). (LA1) were obtained from Millipore (Billerica, MA). Accumulated evidence suggests that GABABR is implicated Pertussis toxin (PTX) and MMP inhibitor GM6001 [ilomastat in human cancers. The level of GABABR in thyroid and breast (Galardin)] were purchased from Millipore. GABABR agonist baclofen, cancer specimens is positively correlated with tumor malig- antagonist CGP54626, PAMs CGP7930, rac-BHFF, and GS39783 nancy (Roberts et al., 2009; Jiang et al., 2012); moreover, were obtained from Tocris Bioscience (Bristol, UK). EGFR inhibitors GABABR increases the metastasis of mouse breast 4T1 cancer Tarceva (erlotinib) and Iressa (gefitinib) were from Active Biochem cells in vivo (Zhang et al., 2014). In contrast, the level of (Hong Kong, People’s Republic of China). GABAB1 subunit in cholangiocarcinoma tissues is negatively correlated with the degree of cell differentiation, local in- Cell Culture vasion, and lymph node metastasis (Huang et al., 2013). Human PCa cell line PC-3 was purchased from American Type Upregulated expression of the GABAB2 subunit is detected in Culture Collection (Manassas, VA). Cells were maintained in F-12 Downloaded from female lung cancer patients with better outcome (Zhang et al., medium (ThermoFisher Scientific, Waltham, MA) supplemented with 2013), whereas the level of GABABR has no obvious correlation 10% fetal bovine serum (FBS; ThermoFisher Scientific), 100 units/ml with the pathologic features of human gastric cancer (Zhu et al., penicillin, and 100 mg/ml streptomycin (ThermoFisher Scientific) at 2004). In vitro studies reveal that GABABR agonists may inhibit 37°C with 5% CO2. Cells were split every 3–4 days and medium was (Fava et al., 2005; Wang et al., 2008; Huang et al., 2013; Zhang replaced every 2 days. et al., 2013; Shu et al., 2016) or display no effect (Abdul et al., 2008; molpharm.aspetjournals.org Lodewyks et al., 2011; Zhang et al., 2014) on the proliferation of Treatment of Cells with Various Compounds cancer cells. Activation of GABA R may promote (Azuma et al., B Â 5 2003; Inamoto et al., 2007; Zhang et al., 2014), suppress (Fava A total of 1.5 10 cells were seeded into 3.5-cm plates and grown in complete medium for 2 days at 37°C with 5% CO . Cells were then et al., 2005; Schuller et al., 2008b,c; Lodewyks et al., 2011), or have 2 serum starved for 24 hours followed by incubation with u7 serum-free no influences (Joseph et al., 2002; Drell et al., 2003; Chen et al., medium (SFM) for 30 minutes before being treated with various 2012) on the migration and/or invasion of cancer cells. These compounds, as described below. observations suggest that the roles of GABABRincancercell GABABR Agonist. Cells were incubated with 200 mM baclofen at proliferation, migration, and tumor malignancy are controversial. 37°C for 0, 1, 5, 10, 20, 30, 60, and 120 minutes or with 0, 50, 100, 150, It has been well documented that GPCRs induce the trans- 200, 250, and 300 mM baclofen at 37°C for 5 minutes. activation of various receptor tyrosine kinases (RTKs) in- PAMs of GABABR. CGP7930, rac-BHFF, and GS39783 were at ASPET Journals on September 28, 2021 cluding epithelial growth factor receptor (EGFR) family solubilized in dimethylsulfoxide (DMSO) with stock concentrations of m members, insulin-like growth factor receptor 1 (IGF-1R), 100, 100, and 10 mM, respectively. Cells were treated with 50 M CGP7930, 100 mM rac-BHFF, or 10 mM GS39783 at 37°C for 0, 1, 5, 10, fibroblast growth
Load more

Recommended publications
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • GABAB Receptor Upregulates Fragile X Mental Retardation Protein
    www.nature.com/scientificreports OPEN GABAB receptor upregulates fragile X mental retardation protein expression in neurons Received: 28 November 2014 1, 1, 1, 1 1 1 Accepted: 15 April 2015 Wenhua Zhang *, Chanjuan Xu *, Haijun Tu *, Yunyun Wang , Qian Sun , Ping Hu , 1 2 1 Published: 28 May 2015 Yongjian Hu , Philippe Rondard & Jianfeng Liu Fragile X mental retardation protein (FMRP) is an RNA-binding protein important for the control of translation and synaptic function. The mutation or silencing of FMRP causes Fragile X syndrome (FXS), which leads to intellectual disability and social impairment. γ -aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the mammalian central nervous system, and its metabotropic GABAB receptor has been implicated in various mental disorders. The GABAB receptor agonist baclofen has been shown to improve FXS symptoms in a mouse model and in human patients, but the signaling events linking the GABAB receptor and FMRP are unknown. In this study, we found that GABAB receptor activation upregulated cAMP response element binding protein-dependent Fmrp expression in cultured mouse cerebellar granule neurons via two distinct mechanisms: the transactivation of insulin-like growth factor-1 receptor and activation of protein kinase C. In addition, a positive allosteric modulator of the GABAB receptor, CGP7930, stimulated Fmrp expression in neurons. These results suggest a role for GABAB receptor in Fmrp regulation and a potential interest of GABAB receptor signaling in FXS improvement. Fragile X mental retardation protein (FMRP) is an RNA-binding protein that controls translation and synaptic function1,2. FMRP mutation or silencing causes Fragile X syndrome (FXS), a common inherited disease associated with autism, intellectual disability, and social impairment3.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION (R,S)-BHFF Item No. 25535 CAS Registry No.: 123557-91-5 Formal Name: 5,7-bis(1,1-dimethylethyl)-3-hydroxy-3- (trifluoromethyl)-2(3H)-benzofuranone Synonym: rac-BHFF MF: C17H21F3O3 O FW: 330.3 Purity: ≥95% O UV/Vis.: λmax: 285 nm OH A crystalline solid Supplied as: CF Storage: -20°C 3 Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures (R,S)-BHFF is supplied as a crystalline solid. A stock solution may be made by dissolving the (R,S)-BHFF in the solvent of choice. (R,S)-BHFF is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of (R,S)-BHFF in these solvents is approximately 30 mg/ml. (R,S)-BHFF is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (R,S)-BHFF should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. (R,S)-BHFF has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description (R,S)-BHFF is a positive allosteric modulator of GABAB receptors that increases the potency of GABA by 35 1 15.3-fold in a GTPγ[ S] binding assay when used at a concentration of 0.3 μM. It is selective for GABAB over a panel of receptors and ion channels at 10 μM, however, it inhibits the cholecystokinin-1 (CCKA) receptor (IC50 = 4.1 μM).
    [Show full text]
  • GABA Receptors
    Tocris Scientific ReviewReview SeriesSeries Tocri-lu-2945 GABA Receptors Ian L. Martin, Norman G. Bowery Historical Perspective and Susan M.J. Dunn GABA is the major inhibitory amino acid transmitter of the Ian Martin is Professor of Pharmacology in the School of Life and mammalian central nervous system (CNS). Essentially all neurons Health Sciences, Aston University, Birmingham, UK. Norman in the brain respond to GABA and perhaps 20% use it as their 1 Bowery is Emeritus Professor of Pharmacology, University of primary transmitter. Early electrophysiological studies, carried Birmingham, UK. Susan Dunn is Professor and Chair at the out using iontophoretic application of GABA to CNS neuronal Department of Pharmacology, Faculty of Medicine and Dentistry, preparations, showed it to produce inhibitory hyperpolarizing 2 University of Alberta, Canada. All three authors share common responses that were blocked competitively by the alkaloid 3 interests in GABAergic transmission. E-mail: sdunn@pmcol. bicuculline. However, in the late 1970s, Bowery and his ualberta.ca colleagues, who were attempting to identify GABA receptors on peripheral nerve terminals, noted that GABA application reduced the evoked release of noradrenalin in the rat heart and that this Contents effect was not blocked by bicuculline. This action of GABA was Introduction ............................................................................................. 1 mimicked, however, by baclofen (Figure 1), a compound that was unable to produce rapid hyperpolarizing responses
    [Show full text]
  • The GABAB Receptor—Structure, Ligand Binding and Drug Development
    molecules Review The GABAB Receptor—Structure, Ligand Binding and Drug Development Linn Samira Mari Evenseth * , Mari Gabrielsen and Ingebrigt Sylte Molecular Pharmacology and Toxicology, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, NO-9037 Tromsø, Norway; [email protected] (M.G.); [email protected] (I.S.) * Correspondence: [email protected] Academic Editor: Mercedes Alfonso-Prieto Received: 29 May 2020; Accepted: 6 July 2020; Published: 7 July 2020 Abstract: The γ-aminobutyric acid (GABA) type B receptor (GABAB-R) belongs to class C of the G-protein coupled receptors (GPCRs). Together with the GABAA receptor, the receptor mediates the neurotransmission of GABA, the main inhibitory neurotransmitter in the central nervous system (CNS). In recent decades, the receptor has been extensively studied with the intention being to understand pathophysiological roles, structural mechanisms and develop drugs. The dysfunction of the receptor is linked to a broad variety of disorders, including anxiety, depression, alcohol addiction, memory and cancer. Despite extensive efforts, few compounds are known to target the receptor, and only the agonist baclofen is approved for clinical use. The receptor is a mandatory heterodimer of the GABAB1 and GABAB2 subunits, and each subunit is composed of an extracellular Venus Flytrap domain (VFT) and a transmembrane domain of seven α-helices (7TM domain). In this review, we briefly present the existing knowledge about the receptor structure, activation and compounds targeting the receptor, emphasizing the role of the receptor in previous and future drug design and discovery efforts. Keywords: GABAB receptors; orthosteric binding site; allosteric binding site; structural mechanisms; drug development; baclofen 1.
    [Show full text]
  • GABA Receptors
    Tocris Scientific Review Series Tocri-lu-2945 GABA Receptors Ian L. Martin, Norman G. Bowery Historical Perspective and Susan M.J. Dunn GABA is the major inhibitory amino acid transmitter of the Ian Martin is Professor of Pharmacology in the School of Life and mammalian central nervous system (CNS). Essentially all neurons Health Sciences, Aston University, Birmingham, UK. Norman in the brain respond to GABA and perhaps 20% use it as their 1 Bowery is Emeritus Professor of Pharmacology, University of primary transmitter. Early electrophysiological studies, carried Birmingham, UK. Susan Dunn is Professor and Chair at the out using iontophoretic application of GABA to CNS neuronal Department of Pharmacology, Faculty of Medicine and Dentistry, preparations, showed it to produce inhibitory hyperpolarizing 2 University of Alberta, Canada. All three authors share common responses that were blocked competitively by the alkaloid 3 interests in GABAergic transmission. E-mail: sdunn@pmcol. bicuculline. However, in the late 1970s, Bowery and his ualberta.ca colleagues, who were attempting to identify GABA receptors on peripheral nerve terminals, noted that GABA application reduced the evoked release of noradrenalin in the rat heart and that this Contents effect was not blocked by bicuculline. This action of GABA was Introduction ............................................................................................. 1 mimicked, however, by baclofen (Figure 1), a compound that was unable to produce rapid hyperpolarizing responses in central
    [Show full text]
  • PR6 2008.Vp:Corelventura
    Pharmacological Reports Copyright © 2008 2008, 60, 755–770 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Review GABAB receptors in drug addiction Ma³gorzata Filip, Ma³gorzata Frankowska Laboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Correspondence: Ma³gorzata Filip, e-mail: [email protected] Abstract: Preclinical studies and clinical trials carried out within the past few years have provided a premise that g-aminobutyric acid (GABA) transmission and GABAB receptors play a modulatory role in the mechanism of action of different drugs of abuse. The present re- view summarizes the contribution of GABAB receptors to the rewarding, locomotor and discriminative stimulus properties of drugs of abuse and their withdrawal symptoms in laboratory animals. It also reviews the current knowledge about the GABAB receptor ligands in clinical trials, with a focus on their effects on presentation of the drug-associated cues and withdrawal-induced drug craving. Key words: addictive substances, discrimination, GABAB receptor ligands, locomotion, reward, reinstatement of seeking behavior, withdrawal, laboratory animals, clinical trials Introduction Recently published data (preclinical studies and clinical trials) have provided a premise that g-amino- butyric acid (GABA) and GABAB receptors play According to the World Health Organization (WHO), a modulatory role in the mechanism of action of dif- drug addiction is a chronic disease of the central nerv- ferent drugs of abuse [4, 35, 70, 102, 132, 147, 158]. ous system that is characterized by a loss of control over impulsive behavior that leads to compulsive drug seeking and taking and to relapses even after many months of abstinence.
    [Show full text]
  • Effects of Co-Administration of the GABAB Receptor Agonist Baclofen
    Pharmacological Reports Copyright © 2013 2013, 65, 11321143 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Effectsofco-administrationoftheGABAB receptoragonistbaclofenandapositiveallosteric modulatoroftheGABAB receptor,CGP7930,on thedevelopmentandexpressionofamphetamine- inducedlocomotorsensitizationinrats LauraN.Cedillo,FlorencioMiranda FESIztacala,NationalAutonomousUniversityofMéxico,Av. delosBarrios1,LosReyesIztacalaTlalnepantla, Edo.deMéxico54090,México Correspondence: FlorencioMiranda,e-mail:[email protected] Abstract: Background: Several of the behavioral effects of amphetamine (AMPH) are mediated by an increase in dopamine neurotransmis- sion in the nucleus accumbens. However, evidence shows that g-aminobutyric acid B (GABAB) receptors are involved in the behav- ioral effects of psychostimulants, including AMPH. Here, we examined the effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on AMPH-induced locomotor sensitization. Methods: In a series of experiments, we examined whether baclofen (2.0, 3.0 and 4.0 mg/kg), CGP7930 (5.0, 10.0 and 20.0 mg/kg), or co-administration of CGP7930 (5.0, 10.0 and 20.0 mg/kg) with a lower dose of baclofen (2.0 mg/kg) could prevent the develop- mentandexpressionoflocomotorsensitizationproducedbyAMPH(1.0mg/kg). Results: The results showed that baclofen treatment prevented both the development and expression of AMPH-induced locomotor sensitization in a dose-dependent manner. Furthermore, the
    [Show full text]
  • Reduction by the Positive Allosteric Modulator of the GABA Receptor
    ORIGINAL RESEARCH ARTICLE published: 19 July 2010 PSYCHIATRY doi: 10.3389/fpsyt.2010.00020 Reduction by the positive allosteric modulator of the GABAB receptor, GS39783, of alcohol self-administration in Sardinian alcohol-preferring rats exposed to the “sipper” procedure Paola Maccioni1†, Paolo Flore 2†, Mauro A. M. Carai1, Claudia Mugnaini 3, Serena Pasquini 3, Federico Corelli 3, Gian Luigi Gessa1 and Giancarlo Colombo1* 1 Consiglio Nazionale delle Ricerche Neuroscience Institute, Cagliari, Italy 2 Department of Neuroscience, University of Cagliari, Cagliari, Italy 3 Department of Pharmaceutical and Applied Chemistry, University of Siena, Siena, Italy Edited by: The present study was designed to evaluate (a) alcohol self-administration behavior of selectively Lorenzo Leggio, Brown University, USA bred, Sardinian alcohol-preferring (sP) rats exposed to the so-called “sipper” procedure Reviewed by: (characterized by the temporal separation between alcohol-seeking and -taking phases), and Malgorzata Filip, Polish Academy of Sciences, Poland (b) the effect of the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol Maria E. Quintanilla, Universidad de self-administration in sP rats exposed to this procedure. To this end, sP rats were initially trained Chile, Chile to lever-respond under a reinforcement requirement (RR) 55 (RR55) for alcohol. Achievement *Correspondence: of RR55 resulted in the 20-min presentation of the alcohol (15%, v/v)-containing sipper bottle. Giancarlo Colombo, Consiglio Once stable levels of lever-responding and alcohol consumption were reached, rats were treated Nazionale delle Ricerche Neuroscience Institute, Viale Diaz 182, I-09126, with 0, 25, 50, and 100 mg/kg GS39783 (i.g.) 60 min before the self-administration session.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,718 B2 Lee Et Al
    USO09526718B2 (12) United States Patent (10) Patent No.: US 9,526,718 B2 Lee et al. (45) Date of Patent: Dec. 27, 2016 (54) COMBINATION OF EFFECTIVE (56) References Cited SUBSTANCES CAUSING SYNERGISTC EFFECTS OF MULTIPLE TARGETING AND U.S. PATENT DOCUMENTS USE THEREOF 2003/0235589 A1* 12/2003 Demopulos .......... A61K9/0019 424,178.1 (75) Inventors: Doo Hyun Lee, Seoul (KR); Sunyoung 2007/O123544 A1* 5/2007 Plourde et al. ............ 514,2611 Cho, Gyeonggi-do (KR) 2008/0242682 A1 10/2008 Hirai et al. 2010/0311674 A1 12/2010 Zhang 2011/O152205 A1* 6/2011 Liang ................... A61K 31,352 (73) Assignee: VIVOZON, INC., Seoul (KR) 514, 23 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 CN 101721589 A * 6, 2010 U.S.C. 154(b) by 277 days. JP 2005-526O79. A 9, 2005 JP 2008-531714 A 8, 2008 (21) Appl. No.: 14/128,616 KR 10-2007-0079497 A 7/2007 KR 10-2007-0085973 A 8, 2007 KR 10-2009-01-13462 A 2, 2009 (22) PCT Filed: Jun. 28, 2012 KR 10-2010-00091206. A 8, 2010 WO O3O77897 A1 9, 2003 (86). PCT No.: PCT/KR2O12/OOS145 WO 2006096434 A2 9, 2006 S 371 (c)(1), (2), (4) Date: Jan. 16, 2014 OTHER PUBLICATIONS Houghton et al., a GlyT2 inhibitor, Org 25543, reduces mechanical (87) PCT Pub. No.: WO2013/002584 allodynia in neuropathic rats. Society for Neuroscience Abstracts, PCT Pub. Date: Jan. 3, 2013 (2001) vol. 27, No. 1, pp. 741.* Baek, N., et al., “Effects of Several Medicinal Plants on the Activity (65) Prior Publication Data of GABA-metabolizing Enzymes”, “Kor.
    [Show full text]
  • Phd Antonia Asimakopoulou.Pdf
    ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΦΑΡΜΑΚΕΥΤΙΚΗΣ Φαρμακολογικός χαρακτηρισμός ουσιών που μεταβάλλουν τα επίπεδα H 2 S: μεταβολές στην κυτταρική σηματοδότηση και επιπτώσεις στις κυτταρικές λειτουργίες. ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ ΑΣΗΜΑΚΟΠΟΥΛΟΥ ΑΝΤΩΝΙΑ ΧΗΜΙΚΟΣ, MSc ΠΑΤΡΑ 2017 ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΦΑΡΜΑΚΕΥΤΙΚΗΣ Φαρμακολογικός χαρακτηρισμός ουσιών που μεταβάλλουν τα επίπεδα H 2 S: μεταβολές στην κυτταρική σηματοδότηση και επιπτώσεις στις κυτταρικές λειτουργίες. ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ H παρούσα έρευνα έχει συγχρηματοδοτηθεί από την Ευρωπαϊκή Ένωση (Ευρωπαϊκό Κοινωνικό Ταμείο - ΕΚΤ) και από εθνικούς πόρους μέσω του Επιχειρησιακού Προγράμματος «Εκπαίδευση και Δια Βίου Μάθηση» του Εθνικού Στρατηγικού Πλαισίου Αναφοράς (ΕΣΠΑ) – Ερευνητικό Χρημα τοδοτούμενο Έργο: ΘΑΛΗΣ: «Υδρόθειο (H 2 S) ένας νέος ενδογενής ρυθμιστής της αγγειογένεσης: μελέτες σηματοδότησης, φυσιολογικοί και παθοφυσιολογικοί ρόλοι και ανάπτυξη φαρμακολογικών αναστολέων». MIS : 380259, Φ.Κ.: D 554 ΑΣΗΜΑΚΟΠΟΥΛΟΥ ΑΝΤΩΝΙΑ ΧΗΜΙΚΟΣ, MSc ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Φαρμακολογικός χαρακτηρισμός ουσιών που μεταβάλλουν τα επίπεδα H 2 S: μεταβολές στην κυτταρική σηματοδότηση και επιπτώσεις στις κυτταρικές λειτουργίες. ΕΞΕΤΑΣΤΙΚΗ ΕΠΙΤΡΟΠΗ ΤΟΠΟΥΖΗΣ ΣΤΑΥΡΟΣ ΑΝΑΠΛΗΡΩΤΗΣ ΚΑΘΗΓΗΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΗΣ ΠΑΝ/ΜΙΟΥ ΠΑΤΡΩΝ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ ΠΑΠΑΠΕΤΡΟΠΟΥΛΟΣ ΑΝΔΡΕΑΣ ΚΑΘΗΓΗΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΗΣ ΕΚΠΑ ΜΕΛΟΣ ΤΡΙΜΕΛΟΥΣ ΣΥΜΒΟΥΛΕΥΤΙΚΗΣ ΕΠΙΤΡΟΠΗΣ ΣΠΥΡΟΥΛΙΑΣ ΓΕΩΡΓΙΟΣ ΚΑΘΗΓΗΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΗΣ ΠΑΝ/ΜΙΟΥ ΠΑΤΡΩΝ ΜΕΛΟΣ ΤΡΙΜΕΛΟΥΣ ΣΥΜΒΟΥΛΕΥΤΙΚ ΗΣ ΕΠΙΤΡΟΠΗΣ ΚΥΠΡΑΙΟΣ ΚΥΡΙΑΚΟΣ ΚΑΘΗΓΗΤΗΣ ΙΑΤΡΙΚΗΣ ΠΑΝ/ΜΙΟΥ
    [Show full text]
  • Every Accomplishment Starts with the Decision to Try
    “Every accomplishment starts with the decision to try. The challenge is not to go where the path may lead, but to go instead where there is no path and leave a trail.” Ralph Waldo Emerson Colophon: Author: Rama Mohamed Kamal Design and lay-out: Mirakels Ontwerp Cover Design: Gildeprint - The Netherlands Printing: Gildeprint - The Netherlands ISBN: ©Rama Mohamed Kamal, 2016 All rights reserved. No part of this publication may be reproduced or transmitted in any form by any means, without permission of the author. THE DETOXIFICATION APPROACH FOR PATIENTS WITH GHB DEPENDENCE Rama Mohamed Kamal Promotoren: Prof. dr. C.A.J. de Jong Prof. dr. A.J.M. Loonen (RUG) Copromotoren: Dr. A.F.A. Schellekens Dr. B.A.G. Dijkstra Manuscriptcommissie: Prof. dr. R.P.C. Kessels Prof. dr. J.K. Buitelaar Prof. dr. B. Wilffert (RUG) THE DETOXIFICATION APPROACH FOR PATIENTS WITH GHB DEPENDENCE PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Radboud Universiteit Nijmegen op gezag van de rector magnificus, volgens besluit van het college van decanen in het openbaar te verdedigen op woensdag 3 februari 2016 om 12.30 uur precies door Rama Mohamed Kamal geboren op 8 juni, 1971 te Omdurman (Sudan) Supervisors: Prof. dr. C.A.J. de Jong Prof. dr. A.J.M. Loonen (RUG) Co-supervisors: Dr. A.F.A. Schellekens Dr. B.A.G. Dijkstra Doctoral Thesis Committee: Prof. dr. R.P.C. Kessels Prof. dr. J.K. Buitelaar Prof. dr. B. Wilffert (RUG) THE DETOXIFICATION APPROACH FOR PATIENTS WITH GHB DEPENDENCE DOCTORAL THESIS to obtain the degree of doctor from Radboud University
    [Show full text]